Furthermore, as a negative or positive regulator of CD93, high serum EV-derived miRNA-5193 or C1qA were associated with favorable or unfavorable PFS after anti-PD-1 therapy in lung cancer patients, which suggests that CD93 is also relative to responses to anti-PD-1 therapy in lung tumor patients and anti-CD93 probably efficiently enhance clinical responses to anti-PD-1 treatment in lung tumor patients. This evidence concerns the gene C1QA and lung carcinoma.